Diamyd Medical AB

Diamyd Medical AB
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes. The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Contacts

Ulf Hannelius

CEO

Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
https://www.diamyd.com
press@diamyd.com

Links

Diamyd Medcial

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Quarterly Report 2 25/26

Wed, Mar 25, 2026 08:15 CET

September 2025 – February 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026Precision Medicine for type 1 diabetes Fully enrolled registrational Phase 3 programDiamyd Medical develops a proprietary platform of precision medicines for type 1 diabetes, a progressive autoimmune disease in which the immune system destroys the body’s own insulin production. The Company is advancing the fully enrolled registrational Phase 3 trial DIAGNODE-3 in the United States and Europe with an upcoming interim readout end of March 2026. Diamyd Medical’s B-share is traded on Nasdaq First North

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Contacts

Links

Quarterly Report 2 25/26

Subscribe